Advertisement
Screener

SCYNEXIS, Inc. (SCYX) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

SCYNEXIS, Inc. Research and Development Expense

SCYNEXIS, Inc. (SCYX) reported Research and Development Expense of $3.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10

  • SCYNEXIS, Inc. research and development expense for the quarter ending 2026-06-30 was $3.89M, a 45.51% decline year-over-year.
  • SCYNEXIS, Inc. research and development expense for the quarter ending 2026-03-31 was $12.35M, a 140.25% increase year-over-year.
  • SCYNEXIS, Inc. research and development expense for the quarter ending 2025-12-31 was $4.54M, a 5.35% increase year-over-year.
  • SCYNEXIS, Inc. research and development expense for the quarter ending 2025-09-30 was $5.45M, a 32.47% decline year-over-year.
  • SCYNEXIS, Inc. research and development expense for fiscal 2025 was $22.28M, a 15.62% decline from fiscal 2024.
  • SCYNEXIS, Inc. research and development expense for fiscal 2024 was $26.41M, a 14.62% decline from fiscal 2023.
  • SCYNEXIS, Inc. research and development expense for fiscal 2023 was $30.93M, a 13.46% increase from fiscal 2022.
  • SCYNEXIS, Inc. research and development expense for fiscal 2022 was $27.26M, a 14.66% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$3.89M
10-Q · filed 2026-08-10
$16.24M
10-Q · filed 2026-08-10
$20.79M
derived: sum of 3 quarters · filed 2026-08-10
$26.24M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$12.35M
10-Q · filed 2026-05-11
$16.90M
derived: sum of 2 quarters · filed 2026-05-11
$22.35M
derived: sum of 3 quarters · filed 2026-05-11
$29.49M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$4.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$10.00M
derived: sum of 2 quarters · filed 2026-03-04
$17.14M
derived: sum of 3 quarters · filed 2026-08-10
$22.28M
10-K · filed 2026-03-04
2025-09-30$5.45M
10-Q · filed 2025-11-05
$12.59M
derived: sum of 2 quarters · filed 2026-08-10
$17.73M
10-Q · filed 2025-11-05
$22.05M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$7.14M
10-Q · filed 2026-08-10
$12.28M
10-Q · filed 2026-08-10
$16.60M
derived: sum of 3 quarters · filed 2026-08-10
$24.67M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$5.14M
10-Q · filed 2026-05-11
$9.46M
derived: sum of 2 quarters · filed 2026-05-11
$17.53M
derived: sum of 3 quarters · filed 2026-05-11
$24.34M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$4.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$12.39M
derived: sum of 2 quarters · filed 2026-03-04
$19.19M
derived: sum of 3 quarters · filed 2026-03-04
$26.41M
10-K · filed 2026-03-04
2024-09-30$8.07M
10-Q · filed 2025-11-05
$14.88M
derived: sum of 2 quarters · filed 2025-11-05
$22.09M
10-Q · filed 2025-11-05
$32.68M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$6.81M
10-Q · filed 2025-08-13
$14.02M
10-Q · filed 2025-08-13
$24.61M
derived: sum of 3 quarters · filed 2025-08-13
$31.07M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$7.21M
10-Q · filed 2025-05-15
$17.80M
derived: sum of 2 quarters · filed 2025-05-15
$24.26M
derived: sum of 3 quarters · filed 2025-05-15
$31.30M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$10.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12
$17.05M
derived: sum of 2 quarters · filed 2025-03-12
$24.09M
derived: sum of 3 quarters · filed 2025-03-12
$30.93M
10-K · filed 2025-03-12
2023-09-30$6.47M
10-Q · filed 2024-11-06
$13.51M
derived: sum of 2 quarters · filed 2024-11-06
$20.34M
10-Q · filed 2024-11-06
$28.19M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30$7.04M
10-Q · filed 2024-08-08
$13.88M
10-Q · filed 2024-08-08
$21.72M
derived: sum of 3 quarters · filed 2024-08-08
$28.15M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$6.83M
10-Q · filed 2024-05-08
$14.68M
derived: sum of 2 quarters · filed 2024-05-08
$21.11M
derived: sum of 3 quarters · filed 2024-05-08
$28.25M
derived: sum of 4 quarters · filed 2024-05-08
2022-12-31$7.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
$14.28M
derived: sum of 2 quarters · filed 2024-03-28
$21.41M
derived: sum of 3 quarters · filed 2024-03-28
$27.26M
10-K · filed 2024-03-28
2022-09-30$6.43M
10-Q · filed 2023-11-13
$13.56M
derived: sum of 2 quarters · filed 2023-11-13
$19.41M
10-Q · filed 2023-11-13
$26.99M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$7.13M
10-Q · filed 2023-08-14
$12.98M
10-Q · filed 2023-08-14
$20.56M
derived: sum of 3 quarters · filed 2023-08-14
$24.96M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$5.74M
10-Q · filed 2023-05-10
$13.43M
derived: sum of 2 quarters · filed 2023-05-10
$17.83M
derived: sum of 3 quarters · filed 2023-05-10
$22.56M
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31$7.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$12.09M
derived: sum of 2 quarters · filed 2023-03-31
$16.82M
derived: sum of 3 quarters · filed 2023-03-31
$23.77M
10-K · filed 2023-03-31
2021-09-30$4.40M
10-Q · filed 2022-11-09
$9.13M
derived: sum of 2 quarters · filed 2022-11-09
$16.08M
10-Q · filed 2022-11-09
$26.24M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$4.73M
10-Q · filed 2022-08-15
$11.68M
10-Q · filed 2022-08-15
$21.84M
derived: sum of 3 quarters · filed 2022-08-15
$29.87M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$6.95M
10-Q · filed 2022-05-12
$17.11M
derived: sum of 2 quarters · filed 2022-05-12
$25.14M
derived: sum of 3 quarters · filed 2022-05-12
$33.60M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$10.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29
$18.19M
derived: sum of 2 quarters · filed 2022-03-29
$26.66M
derived: sum of 3 quarters · filed 2022-03-29
$36.52M
10-K · filed 2022-03-29
2020-09-30$8.03M
10-Q · filed 2021-11-10
$16.50M
derived: sum of 2 quarters · filed 2021-11-10
$26.36M
10-Q · filed 2021-11-10
$37.33M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$8.47M
10-Q · filed 2021-08-16
$18.34M
10-Q · filed 2021-08-16
$29.30M
derived: sum of 3 quarters · filed 2021-08-16
$38.57M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$9.87M
10-Q · filed 2021-05-17
$20.83M
derived: sum of 2 quarters · filed 2021-05-17
$30.10M
derived: sum of 3 quarters · filed 2021-05-17
$38.58M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$10.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$20.24M
derived: sum of 2 quarters · filed 2021-03-29
$28.71M
derived: sum of 3 quarters · filed 2021-03-29
$38.39M
10-K · filed 2021-03-29
2019-09-30$9.28M
10-Q · filed 2020-11-06
$17.75M
derived: sum of 2 quarters · filed 2020-11-06
$27.43M
10-Q · filed 2020-11-06
$34.14M
derived: sum of 4 quarters · filed 2020-11-06
2019-06-30$8.47M
10-Q · filed 2020-08-10
$18.16M
10-Q · filed 2020-08-10
$24.86M
derived: sum of 3 quarters · filed 2020-08-10
$28.79M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$9.68M
10-Q · filed 2020-05-11
$16.39M
derived: sum of 2 quarters · filed 2020-05-11
$20.32M
derived: sum of 3 quarters · filed 2020-05-11
$25.92M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$6.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11
$10.63M
derived: sum of 2 quarters · filed 2020-03-11
$16.23M
derived: sum of 3 quarters · filed 2020-03-11
$21.56M
10-K · filed 2020-03-11
2018-09-30$3.93M
10-Q · filed 2019-11-12
$9.53M
derived: sum of 2 quarters · filed 2019-11-12
$14.86M
10-Q · filed 2019-11-12
$20.26M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$5.60M
10-Q · filed 2019-08-07
$10.93M
10-Q · filed 2019-08-07
$16.32M
derived: sum of 3 quarters · filed 2019-08-07
$20.78M
derived: sum of 4 quarters · filed 2019-08-07
2018-03-31$5.33M
10-Q · filed 2019-05-08
$10.72M
derived: sum of 2 quarters · filed 2019-05-08
$15.18M
derived: sum of 3 quarters · filed 2019-05-08
$19.63M
derived: sum of 4 quarters · filed 2019-05-08
2017-12-31$5.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14
$9.86M
derived: sum of 2 quarters · filed 2019-03-14
$14.31M
derived: sum of 3 quarters · filed 2019-03-14
$18.33M
10-K · filed 2019-03-14
2017-09-30$4.46M
10-Q · filed 2018-11-13
$8.91M
derived: sum of 2 quarters · filed 2018-11-13
$12.93M
10-Q · filed 2018-11-13
$16.71M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30$4.45M
10-Q · filed 2018-08-09
$8.47M
10-Q · filed 2018-08-09
$12.25M
derived: sum of 3 quarters · filed 2018-08-09
$17.14M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$4.02M
10-Q · filed 2018-05-08
$7.80M
derived: sum of 2 quarters · filed 2018-05-08
$12.69M
derived: sum of 3 quarters · filed 2018-05-08
$19.35M
derived: sum of 4 quarters · filed 2018-05-08
2016-12-31$3.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13
$8.67M
derived: sum of 2 quarters · filed 2018-03-13
$15.33M
derived: sum of 3 quarters · filed 2018-03-13
$20.08M
10-K · filed 2018-03-13
2016-09-30$4.89M
10-Q · filed 2017-11-07
$11.55M
derived: sum of 2 quarters · filed 2017-11-07
$16.29M
10-Q · filed 2017-11-07
$22.21M
derived: sum of 4 quarters · filed 2017-11-07
2016-06-30$6.66M
10-Q · filed 2017-08-08
$11.40M
10-Q · filed 2017-08-08
$17.32M
derived: sum of 3 quarters · filed 2017-08-08
$20.77M
derived: sum of 4 quarters · filed 2017-08-08
2016-03-31$4.74M
10-Q · filed 2017-05-08
$10.66M
derived: sum of 2 quarters · filed 2017-05-08
$14.12M
derived: sum of 3 quarters · filed 2017-05-08
$17.40M
derived: sum of 4 quarters · filed 2017-05-08
2015-12-31$5.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13
$9.37M
derived: sum of 2 quarters · filed 2017-03-13
$12.65M
derived: sum of 3 quarters · filed 2017-03-13
$16.44M
10-K · filed 2017-03-13
2015-09-30$3.46M
10-Q · filed 2016-11-07
$6.74M
derived: sum of 2 quarters · filed 2016-11-07
$10.53M
10-Q · filed 2016-11-07
$13.19M
derived: sum of 4 quarters · filed 2017-03-13
2015-06-30$3.28M
10-Q · filed 2016-08-08
$7.07M
10-Q · filed 2016-08-08
$9.73M
derived: sum of 3 quarters · filed 2017-03-13
$12.21M
derived: sum of 4 quarters · filed 2017-03-13
2015-03-31$3.79M
10-Q · filed 2016-05-09
$4.22M
10-Q · filed 2015-05-15
$6.45M
derived: sum of 2 quarters · filed 2017-03-13
$8.93M
derived: sum of 3 quarters · filed 2017-03-13
$10.75M
derived: sum of 4 quarters · filed 2017-03-13
2014-12-31$2.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13
$5.14M
derived: sum of 2 quarters · filed 2017-03-13
$6.97M
derived: sum of 3 quarters · filed 2017-03-13
$8.29M
10-K · filed 2017-03-13
2014-09-30$2.48M
10-Q · filed 2015-11-13
$4.30M
derived: sum of 2 quarters · filed 2015-11-13
$5.62M
10-Q · filed 2015-11-13
$6.78M
derived: sum of 4 quarters · filed 2015-11-13
2014-06-30$1.82M
10-Q · filed 2015-08-19
$3.14M
10-Q · filed 2015-08-19
$4.30M
derived: sum of 3 quarters · filed 2015-10-30
$5.35M
derived: sum of 4 quarters · filed 2015-10-30
2014-03-31$1.32M
8-K · filed 2015-10-30
$2.48M
derived: sum of 2 quarters · filed 2015-10-30
$3.53M
derived: sum of 3 quarters · filed 2015-10-30
$4.53M
derived: sum of 4 quarters · filed 2015-10-30
2013-12-31$1.16M
derived: 8-K 12 month − 10-Q 9 month · filed 2015-10-30
$2.21M
derived: sum of 2 quarters · filed 2015-10-30
$3.21M
derived: sum of 3 quarters · filed 2015-10-30
$4.36M
8-K · filed 2015-10-30
2013-09-30$1.05M
10-Q · filed 2014-11-13
$2.05M
derived: sum of 2 quarters · filed 2014-11-13
$3.20M
10-Q · filed 2014-11-13
2013-06-30$999.00K
10-Q · filed 2014-08-13
$2.15M
10-Q · filed 2014-08-13
2013-03-31$1.15M
10-Q/A · filed 2014-07-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
VERU INC. (VERU)United States$0.043B-3.93
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98